Bad news from the FDA caused investors to head for the hills.
News & Analysis: AVEO Pharmaceuticals
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
The company's meager cash position is worrying investors.
AVEO is close to a key clinical readout that could prove to be a major catalyst for its stock.
Hint: It had nothing to do with the press release. The biotech is presenting at a few upcoming conferences, but only one really matters.
Investors jump in ahead of expected clinical trial data.
Investors are buying into the company's explanation for a delay in clinical trial data.
Sometimes you've got to dig into SEC documents to find the answer.
The company announced a delay concerning its top drug candidate.
Investors see value after last week's decline.